The levels of Th17 markers, such as RORC2, RORα4, IL-17A, IL-17A receptor, and VEGF, were significantly elevated in lung cancer patients25,26, and immune effector T cells (Teff) from small cell lung cancer (SCLC) patients included a large population of Th17 cells27. This evidence concerns the gene IL17A and lung cancer.